AVTR Quote, Financials, Valuation and Earnings

Azenta has a net margin of 29.67% compared to Avantor's net margin of -9.04%. Avantor's return on equity of 12.92% beat Azenta's return on equity of -7.97%.

Avantor has a consensus price target of $24.48, signalling upside risk potential of 48%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 56.03%. Given that Azenta has higher upside potential than Avantor, analysts believe Azenta is more attractive than Avantor.

Avantor has a beta of 1.299, which suggesting that the stock is 29.904% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Azenta quarterly revenues of $147.5M. Avantor's net income of $500.4M is higher than Azenta's net income of -$13.3M. Notably, Avantor's price-to-earnings ratio is 15.90x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.66x versus 2.91x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 29.67% compared to Avantor's net margin of -107.24%. Avantor's return on equity of 12.92% beat Bio-Rad Laboratories's return on equity of -23.87%.

Avantor has a consensus price target of $24.48, signalling upside risk potential of 48%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $372.83 which suggests that it could grow by 45.25%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.

Avantor has a beta of 1.299, which suggesting that the stock is 29.904% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.984, suggesting its less volatile than the S&P 500 by 1.622%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Avantor's net income of $500.4M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Avantor's price-to-earnings ratio is 15.90x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.66x versus 2.82x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 29.67% compared to Avantor's net margin of 1.4%. Avantor's return on equity of 12.92% beat Bruker's return on equity of 6.78%.

Avantor has a consensus price target of $24.48, signalling upside risk potential of 48%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 54.06%. Given that Bruker has higher upside potential than Avantor, analysts believe Bruker is more attractive than Avantor.

Avantor has a beta of 1.299, which suggesting that the stock is 29.904% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.45% to investors and pays a quarterly dividend of $0.05 per share. Avantor pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Avantor quarterly revenues are $1.7B, which are larger than Bruker quarterly revenues of $979.6M. Avantor's net income of $500.4M is higher than Bruker's net income of $13.7M. Notably, Avantor's price-to-earnings ratio is 15.90x while Bruker's PE ratio is 58.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.66x versus 1.97x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 29.67% compared to Avantor's net margin of 0.07%. Avantor's return on equity of 12.92% beat Harvard Bioscience's return on equity of -18.36%.

Avantor has a consensus price target of $24.48, signalling upside risk potential of 48%. On the other hand Harvard Bioscience has an analysts' consensus of $4.25 which suggests that it could grow by 568.13%. Given that Harvard Bioscience has higher upside potential than Avantor, analysts believe Harvard Bioscience is more attractive than Avantor.

Avantor has a beta of 1.299, which suggesting that the stock is 29.904% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.371%.

Avantor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avantor pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Avantor quarterly revenues are $1.7B, which are larger than Harvard Bioscience quarterly revenues of $24.6M. Avantor's net income of $500.4M is higher than Harvard Bioscience's net income of $18K. Notably, Avantor's price-to-earnings ratio is 15.90x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avantor is 1.66x versus 0.29x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.